Yanning Wang1, Chris Delcher2, Yan Li3, Bruce A Goldberger4, Gary M Reisfield5. 1. Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL 32610, United States. Electronic address: ynwang@ufl.edu. 2. Department of Pharmacy Practice and Science, Institute for Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Kentucky, Lexington, KY 40536, United States. 3. Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida 32610, United States. 4. Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida and UF Health Forensic Medicine, Gainesville, FL 32610, United States. 5. Department of Psychiatry, College of Medicine, University of Florida, Gainesville, Florida 32610, United States.
Abstract
BACKGROUND: High-risk combinations of controlled medications, such as those involving opioid analgesics, are under increased scrutiny because of their contribution to the opioid epidemic in the United States. Responsible prescribing guidelines indicate that the triple drug combination--opioids, benzodiazepines and skeletal muscle relaxants, especially carisoprodol--should not be concurrently prescribed. METHODS: This pharmacoepidemiologic study was designed to primarily examine the characteristics of patients receiving this triple combination compared to the group receiving only opioids and benzodiazepines. RESULTS: Results show that, while the number of exposed patients has declined since 2012, approximately 17,000 Floridians were prescribed this combination in 2017 alone. Demographically, recipients of these prescriptions were younger, more likely to be female, and geographically-localized. Furthermore, these patients were more frequently associated with a prescriber in the top 1% of opioid and/or benzodiazepine prescribing, have more multiple provider episodes ("doctor shopping"), and receive higher mean daily opioid dosages. CONCLUSIONS: These findings raise important questions as to how frequently prescribers are checking prescription drug monitoring programs, following US Centers for Disease Control and Prevention opioid prescribing guidelines, and/or handling the clinical challenges associated with pharmaceutical management of patients with complex, painful health conditions.
BACKGROUND: High-risk combinations of controlled medications, such as those involving opioid analgesics, are under increased scrutiny because of their contribution to the opioid epidemic in the United States. Responsible prescribing guidelines indicate that the triple drug combination--opioids, benzodiazepines and skeletal muscle relaxants, especially carisoprodol--should not be concurrently prescribed. METHODS: This pharmacoepidemiologic study was designed to primarily examine the characteristics of patients receiving this triple combination compared to the group receiving only opioids and benzodiazepines. RESULTS: Results show that, while the number of exposed patients has declined since 2012, approximately 17,000 Floridians were prescribed this combination in 2017 alone. Demographically, recipients of these prescriptions were younger, more likely to be female, and geographically-localized. Furthermore, these patients were more frequently associated with a prescriber in the top 1% of opioid and/or benzodiazepine prescribing, have more multiple provider episodes ("doctor shopping"), and receive higher mean daily opioid dosages. CONCLUSIONS: These findings raise important questions as to how frequently prescribers are checking prescription drug monitoring programs, following US Centers for Disease Control and Prevention opioid prescribing guidelines, and/or handling the clinical challenges associated with pharmaceutical management of patients with complex, painful health conditions.
Authors: Cheng Chen; Sean Hennessy; Colleen M Brensinger; Ghadeer K Dawwas; Emily K Acton; Warren B Bilker; Sophie P Chung; Sascha Dublin; John R Horn; Todd A Miano; Thanh Phuong Pham Nguyen; Samantha E Soprano; Charles E Leonard Journal: Br J Clin Pharmacol Date: 2022-06-01 Impact factor: 3.716
Authors: Emily K Acton; Sean Hennessy; Colleen M Brensinger; Warren B Bilker; Todd A Miano; Sascha Dublin; John R Horn; Sophie Chung; Douglas J Wiebe; Allison W Willis; Charles E Leonard Journal: Front Pharmacol Date: 2022-05-10 Impact factor: 5.988
Authors: Chris Delcher; Daniel R Harris; Changwe Park; Gail K Strickler; Jeffery Talbert; Patricia R Freeman Journal: Drug Alcohol Depend Date: 2021-02-15 Impact factor: 4.492